Hibsago (bepirovirsen)

Chronic hepatitis B virus infection in adults without cirrhosis

Also known as GSK3228836

Manufacturer: GSK
Regulatory status: ApprovedNDA submitted in the first quarter of 2026 and approved October 2026
Launch: Anticipated before the end of 2026
Last updated: October 22, 2026

Section

Product information and disease description Product description

Product information

193 evidence topics · 57 sources

Generic, brand name and therapeutic class of product8 evidence topics · 8 sources
Dosage forms and strengths6 evidence topics · 1 source
Average sales price and wholesale acquisition cost8 evidence topics · 4 sources
American hospital formulary service (AHFS), or other drug classification3 evidence topics · 2 sources
Indication9 evidence topics · 5 sources
Pharmacology47 evidence topics · 15 sources
Contraindications/Warnings/Precautions/Adverse effects25 evidence topics · 2 sources
Special populations12 evidence topics · 5 sources
Drug/Drug, drug/disease interactions13 evidence topics · 3 sources
Dosing and administration17 evidence topics · 4 sources
Access and distribution5 evidence topics · 5 sources
Co-prescribed/Concomitant therapies9 evidence topics · 6 sources
Effect of bepirovirsen on quality measures8 evidence topics · 8 sources
Product comparison23 evidence topics · 18 sources